Program
SAT-3247
A development code.
Its studies are mostly in Muscular Dystrophy, Duchenne, led by Satellos Bioscience.
Furthest: phase 2, since Mar 4, 20253 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Satellos Bioscience | 32 open or running | phase 2since Mar 4, 2025 | Aug 19, 2024 | Mar 31, 2027phase 2 · NCT07287189 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 19, 2024First study: early phase 1 study in Muscular Dystrophy, DuchenneFirst studyNCT06565208 · 77 enrolled · Australia
- Mar 4, 2025Phase 2 study in Muscular Dystrophy, DuchenneNCT06867107 · 30 planned · United States, Australia
- Dec 11, 2025Phase 2 study in Muscular Dystrophy, DuchenneNCT07287189 · 51 enrolled · United States, Australia, Belgium and more
Ahead
- Mar 31, 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT07287189
- Sep 30, 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06867107
TargetBeta
AAK1 →read by rule
“SAT-3247 is a selective AAK1 inhibitor for oral tablet administration which promotes functional rescue of asymmetric satellite cell division, resulting in the robust production of muscle progenitor cells, subsequent improvement in muscle regeneration, and enhanced muscle function.”study text, by rule · the study
Other programs on AAK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Forazapadinrule | Satellos Bioscience | phase 2 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07287189Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more | 2 | Active, not recruiting | Mar 31, 2027 | 51 |
| NCT06867107Muscular Dystrophy, Duchenne · United States, Australia | 2 | By invitation | Sep 30, 2027 | 30 |
| NCT06565208Muscular Dystrophy, Duchenne · Australia | Early 1 | Completed | Apr 28, 2025 | 77 |
How it is read
Names in the registry
- “SAT-3247”, 3 entries
Codes read as this program: SAT3247.
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.